Aquestive Therapeutics Capital Expenditures (CapEx) Growth & History (AQST)
Aquestive Therapeutics's capital expenditures (capex) was $562,000 for fiscal 2025.
View full Aquestive Therapeutics company overviewAquestive Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $562,000 | $403,000 | +253.46% |
| 2024 | 2024-12-31 | $159,000 | −$836,000 | −84.02% |
| 2023 | 2023-12-31 | $995,000 | −$29,000 | −2.83% |
| 2022 | 2022-12-31 | $1.0M | $111,000 | +12.16% |
| 2021 | 2021-12-31 | $913,000 | $396,000 | +76.60% |
| 2020 | 2020-12-31 | $517,000 | −$146,000 | −22.02% |
| 2019 | 2019-12-31 | $663,000 | −$1.2M | −63.65% |
| 2018 | 2018-12-31 | $1.8M | −$244,000 | −11.80% |
| 2017 | 2017-12-31 | $2.1M | — | — |
Aquestive Therapeutics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $212,000 | $105,000 | +98.13% |
| Q1 2026 | 2026-03-31 | $52,000 | −$83,000 | −61.48% |
| Q4 2025 | 2025-12-31 | $85,000 | $70,000 | +466.67% |
| Q3 2025 | 2025-09-30 | $235,000 | $155,000 | +193.75% |
| Q2 2025 | 2025-06-30 | $107,000 | $72,000 | +205.71% |
| Q1 2025 | 2025-03-31 | $135,000 | $106,000 | +365.52% |
| Q4 2024 | 2024-12-31 | $15,000 | −$1,000 | −6.25% |
| Q3 2024 | 2024-09-30 | $80,000 | −$71,000 | −47.02% |
| Q2 2024 | 2024-06-30 | $35,000 | −$791,000 | −95.76% |
| Q1 2024 | 2024-03-31 | $29,000 | $27,000 | +1350.00% |
| Q4 2023 | 2023-12-31 | $16,000 | −$10,000 | −38.46% |
| Q3 2023 | 2023-09-30 | $151,000 | −$66,000 | −30.41% |
| Q2 2023 | 2023-06-30 | $826,000 | $149,000 | +22.01% |
| Q1 2023 | 2023-03-31 | $2,000 | −$102,000 | −98.08% |
| Q4 2022 | 2022-12-31 | $26,000 | −$507,000 | −95.12% |
| Q3 2022 | 2022-09-30 | $217,000 | $134,000 | +161.45% |
| Q2 2022 | 2022-06-30 | $677,000 | $483,000 | +248.97% |
| Q1 2022 | 2022-03-31 | $104,000 | $1,000 | +0.97% |
| Q4 2021 | 2021-12-31 | $533,000 | $297,000 | +125.85% |
| Q3 2021 | 2021-09-30 | $83,000 | $45,000 | +118.42% |
| Q2 2021 | 2021-06-30 | $194,000 | $82,000 | +73.21% |
| Q1 2021 | 2021-03-31 | $103,000 | −$28,000 | −21.37% |
| Q4 2020 | 2020-12-31 | $236,000 | $150,000 | +174.42% |
| Q3 2020 | 2020-09-30 | $38,000 | −$53,000 | −58.24% |
| Q2 2020 | 2020-06-30 | $112,000 | $2,000 | +1.82% |
| Q1 2020 | 2020-03-31 | $131,000 | −$245,000 | −65.16% |
| Q4 2019 | 2019-12-31 | $86,000 | −$404,000 | −82.45% |
| Q3 2019 | 2019-09-30 | $91,000 | −$357,000 | −79.69% |
| Q2 2019 | 2019-06-30 | $110,000 | −$517,000 | −82.46% |
| Q1 2019 | 2019-03-31 | $376,000 | $117,000 | +45.17% |
| Q4 2018 | 2018-12-31 | $490,000 | — | — |
| Q3 2018 | 2018-09-30 | $448,000 | $15,000 | +3.46% |
| Q2 2018 | 2018-06-30 | $627,000 | — | — |
| Q1 2018 | 2018-03-31 | $259,000 | — | — |
| Q3 2017 | 2017-09-30 | $433,000 | — | — |
Aquestive Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Aquestive Therapeutics's capital expenditures (capex) increased from $517,000 to $562,000, a change of $45,000. The latest reported quarter, Q2 2026, shows $212,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aquestive Therapeutics source filings ↗